CAL-15

Indications

• Hyperkalemia
• Chronic kidney disease with elevated potassium levels
• Management of certain toxicities (e.g., digoxin toxicity) in conjunction with other treatments

Dosage

Children: Refer to established clinical guidelines for specific pediatric dosing information, as it is based on weight and clinical condition.

Adults: Refer to established clinical guidelines for specific dosing information, as it may vary based on the severity of hyperkalemia and the clinical setting.

Mechanism of action

Sodium polystyrene sulfonate acts as a cation-exchange resin in the intestines, where it exchanges sodium ions for potassium ions. This process facilitates the elimination of potassium from the body through feces, effectively lowering serum potassium concentrations.

Pharmacodynamics

The primary pharmacodynamic effect of sodium polystyrene sulfonate is the reduction of serum potassium levels. The resin binds potassium in the gastrointestinal tract, leading to an increase in potassium excretion. The onset of action can vary; however, the drug generally takes several hours to exert its effects, with peak potassium-lowering effects occurring after a few hours.

Pharmacokinetics

Sodium polystyrene sulfonate is not absorbed systemically; its action is confined to the gastrointestinal tract. The resin passes through the intestines unaltered and is excreted in feces. The duration of action is dependent on the amount of potassium present in the gut and the total resin dose administered. Its elimination is essentially through fecal excretion.

Contra-indications

• Hypokalemia
• Severe gastrointestinal obstruction
• Bowel perforation

Adverse effects

• Electrolyte disturbances
• Gastrointestinal irritation
• Constipation
• Nausea
• Vomiting
• Abdominal discomfort

Interactions

• May decrease the absorption of certain medications due to delayed gastric emptying
• Caution when used with other medications that can affect potassium levels

Precautions

• Use with caution in patients with renal impairment
• Monitor electrolyte levels during therapy
• Ensure adequate hydration to prevent constipation

Pregnancy

Use only if clearly needed and after assessing potential benefits versus risks, as safety during pregnancy has not been fully established.

Breast-feeding

It is not known if polystyrene is excreted in human milk. Use with caution and assess the necessity.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Polystyrene sulfonate (sodium or calcium) in powder form
• Polystyrene sulfonate suspension

Indications

• Adjunct in weight management
• Sugar substitute for diabetics
• Flavoring agent in various food products

Dosage

Children: Refer to the BNF for Children for specific pediatric dosing guidance. Saccharin is often used in pediatric populations as a sugar substitute but should be administered with caution and within recommended limits.

Adults: As saccharin is used as a sweetener rather than a medication, specific dosing guidelines are not typically established. The acceptable daily intake (ADI) is generally considered to be safe within the limits set by health authorities.

Mechanism of action

Saccharin activates specific T2R bitter taste receptors, which are involved in the perception of taste. Additionally, it has been shown to stimulate transient receptor potential vanilloid-1 (TRPV1) receptors, which are present in taste receptor cells and nerve terminals throughout the oral cavity. This activation may contribute to the bitter aftertaste and metallic taste sensations associated with saccharin and similar sweeteners.

Pharmacodynamics

Saccharin's primary pharmacodynamic effect is its intense sweetness, which is mediated through the activation of taste receptors. The stimulation of T2R receptors and TRPV1 channels can lead to varying taste sensations, including sweetness and bitterness. The sweet taste perception occurs through the activation of taste receptor cells that signal through gustatory pathways to the brain, allowing for the recognition of sweet flavors.

Pharmacokinetics

Saccharin is rapidly absorbed from the gastrointestinal tract and is excreted unchanged in urine. It does not undergo significant metabolism, which contributes to its safety profile as a non-caloric sweetener. The elimination half-life and pharmacokinetic parameters are not typically documented due to its minimal systemic effects in the context of sweetening agents.

Adverse effects

• Gastrointestinal disturbances
• Allergic reactions
• Headaches
• Metallic taste

Precautions

• Use with caution in patients with a history of hypersensitivity to sweeteners
• Consider potential for allergic reactions

Pregnancy

Safety during pregnancy has not been established. Use with caution and consult healthcare professionals.

Breast-feeding

Safety during breastfeeding has not been established. Consult healthcare professionals before use.

Storage

Store in a cool, dry place, away from direct sunlight.

Formulations

• Tablets
• Powder

Mechanism of action

Sulphonates exert their effects primarily through the inhibition of certain enzymes or pathways involved in metabolic processes. They may interact with cellular receptors or transporters, leading to alterations in ion transport, enzyme activity, and cellular signaling.

Pharmacodynamics

The pharmacodynamics of sulphonates is largely dependent on their specific structure and the biological targets they interact with. Generally, they may modulate the activity of neurotransmitters, influence the reactivity of free radicals, or affect cellular signaling pathways, contributing to their therapeutic effects.

Pharmacokinetics

Sulphonates are typically absorbed in the gastrointestinal tract, with variable bioavailability depending on the specific compound. They are metabolized primarily in the liver, with subsequent elimination through renal pathways. The half-life and clearance can vary significantly based on the compound's structure and the individual's physiology.

Mechanism of action

Vanillin exerts its effects through various biochemical pathways. It is involved in the vanillin and vanillate degradation pathways, as well as in the biosynthesis of vanillin itself. The compound may interact with specific receptors or enzymes, influencing metabolic processes and exhibiting antioxidant activity.

Pharmacodynamics

Vanillin has been shown to possess antioxidant properties, which help in scavenging free radicals and reducing oxidative stress. Its anti-inflammatory effects are attributed to the modulation of inflammatory pathways, potentially impacting conditions associated with chronic inflammation. Additionally, vanillin may exhibit neuroprotective effects, contributing to brain health.

Pharmacokinetics

Vanillin is absorbed in the gastrointestinal tract and is metabolized primarily in the liver. The compound undergoes phase I metabolism, resulting in various metabolites that may have biological activity. The elimination half-life of vanillin is not well-documented, and further studies are needed to fully elucidate its pharmacokinetic profile.

Pregnancy

Safety during pregnancy has not been established; consult a healthcare provider for advice.

Breast-feeding

Safety during breastfeeding has not been established; consult a healthcare provider for advice.

Storage

Store in a cool, dry place away from direct sunlight. Keep container tightly closed.

Formulations

• Vanillin powder
• Vanillin solution

Mechanism of action

...it has been shown that the activation of particular T2R bitter taste receptors is partially involved with the bitter aftertaste sensation of saccharin and acesulfame-K. ... /This study/ addressed the question of whether /they/ could stimulate transient receptor potential vanilloid-1 (TRPV1) receptors, as these receptors are activated by a large range of structurally different chemicals. Moreover, TRPV1 receptors and/or their variants are found in taste receptor cells and in nerve terminals throughout the oral cavity. Hence, TRPV1 activation could be involved in the ... aftertaste or even contribute to the poorly understood metallic taste sensation. Using Ca(2+) imaging on TRPV1 receptors heterologously expressed in the human embryonic kidney (HEK) 293 cells and on dissociated primary sensory neurons,... /it was found/ that in both systems, .../sweeteners/ activate TRPV1 receptors, and, moreover, they sensitize these channels to acid and heat. ... /it was/also found that TRPV1 receptors were activated by CuSO(4), ZnSO(4), and FeSO(4), three salts known to produce a metallic taste sensation. In summary, .../the/ results identify a novel group of compounds that activate TRPV1 and, consequently, provide a molecular mechanism that may account for off tastes of sweeteners and metallic tasting salts.